Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir H Barghout

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
ACS Chemical Biology|September 9, 2022
Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical ProbesSamir H Barghout, Mandeep K Mann, Ahmed Aman, et al.
Clinical Lung Cancer|November 22, 2024
A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung CancerSze Wah Samuel Chan, Joy Zeng, Jack Young, et al.
Redox Biology|March 19, 2022
PRMT5 regulates ATF4 transcript splicing and oxidative stress responseMagdalena M Szewczyk, Genna M Luciani, Victoria Vu, et al.
JCI Insight|January 21, 2021
A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivitySamir H Barghout, Ahmed Aman, Kazem Nouri, et al.
Haematologica|December 22, 2018
The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemiaDana Yehudai, Sanduni U Liyanage, Rose Hurren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung CancerSafa Majeed, Mansi K Aparnathi, Kevin C J Nixon, et al.
Cancer Treatment and Research Communications|November 18, 2023
Presentation and outcomes of KRAS<sup>G12C</sup> mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrenceNiki Esfahanian, Sze Wah Samuel Chan, Luna J Zhan, et al.
Leukemia|June 10, 2018
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemiaSamir H Barghout, Parasvi S Patel, Xiaoming Wang, et al.
British Journal of Cancer|November 21, 2024
Adaptive Universal Principles for Real-world Observational Studies (AUPROS): an approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology researchSamir H Barghout, Nicholas Meti, Simren Chotai, et al.
Leukemia Research|March 9, 2018
AML refractory to primary induction with Ida-FLAG has a poor clinical outcomeSimon Kavanagh, Emily Heath, Rose Hurren, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
ACS Chemical Biology|September 9, 2022
Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical ProbesSamir H Barghout, Mandeep K Mann, Ahmed Aman, et al.
Clinical Lung Cancer|November 22, 2024
A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung CancerSze Wah Samuel Chan, Joy Zeng, Jack Young, et al.
Redox Biology|March 19, 2022
PRMT5 regulates ATF4 transcript splicing and oxidative stress responseMagdalena M Szewczyk, Genna M Luciani, Victoria Vu, et al.
JCI Insight|January 21, 2021
A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivitySamir H Barghout, Ahmed Aman, Kazem Nouri, et al.
Haematologica|December 22, 2018
The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemiaDana Yehudai, Sanduni U Liyanage, Rose Hurren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Targeting the Ubiquitin-Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung CancerSafa Majeed, Mansi K Aparnathi, Kevin C J Nixon, et al.
Cancer Treatment and Research Communications|November 18, 2023
Presentation and outcomes of KRAS<sup>G12C</sup> mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrenceNiki Esfahanian, Sze Wah Samuel Chan, Luna J Zhan, et al.
Leukemia|June 10, 2018
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemiaSamir H Barghout, Parasvi S Patel, Xiaoming Wang, et al.
British Journal of Cancer|November 21, 2024
Adaptive Universal Principles for Real-world Observational Studies (AUPROS): an approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology researchSamir H Barghout, Nicholas Meti, Simren Chotai, et al.
Leukemia Research|March 9, 2018
AML refractory to primary induction with Ida-FLAG has a poor clinical outcomeSimon Kavanagh, Emily Heath, Rose Hurren, et al.
Pageof 3